A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use
NCT02922543
·
clinicaltrials.gov ↗
COMPLETED
Status
361
Enrollment
INDUSTRY
Sponsor class
Conditions
Multiple Myeloma
Sponsor
Celgene